Session » Antiphospholipid Syndrome Poster
- 9:00AM-11:00AM
-
Abstract Number: 0529
A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies
- 9:00AM-11:00AM
-
Abstract Number: 0520
Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward
- 9:00AM-11:00AM
-
Abstract Number: 0521
Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?
- 9:00AM-11:00AM
-
Abstract Number: 0523
Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members
- 9:00AM-11:00AM
-
Abstract Number: 0524
Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases
- 9:00AM-11:00AM
-
Abstract Number: 0522
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase III Case Collection Results
- 9:00AM-11:00AM
-
Abstract Number: 0525
Epidemiology of Thromboembolic Complications Among Hospitalized Patients with Antiphospholipid Syndrome in the United States
- 9:00AM-11:00AM
-
Abstract Number: 0526
Patient-Reported Outcomes in Antiphospholipid Syndrome
- 9:00AM-11:00AM
-
Abstract Number: 0530
Pediatric APS: Clinical Features, Therapeutic Interventions, and Damage in a Series of 22 Cases
- 9:00AM-11:00AM
-
Abstract Number: 0527
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
- 9:00AM-11:00AM
-
Abstract Number: 0528
The Complex Relationship Between C4b Binding Protein, Warfarin and Antiphospholipid Antibodies